先声再明递表港交所

Group 1 - The core viewpoint of the article is that Xiansheng Zaiming Pharmaceutical Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Morgan Stanley and CICC as joint sponsors [1] - The company, established in 2020, focuses on the research, development, and commercialization of innovative oncology drugs, having five commercialized innovative drugs and over 15 high-potential candidates in clinical and IND application preparation stages [1] - According to a report by Aoyishi Consulting, by 2025, the company is expected to complete three out-licensing transactions, ranking first in the number of oncology asset transactions and fourth in total transaction value among Chinese biopharmaceutical companies [1]